[
    [
        {
            "time": "2018-10-17",
            "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
            "features": {
                "keywords": [
                    "class action",
                    "lawsuit",
                    "shareholders",
                    "investment losses"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "AbbVie, Roche combo treatment meets main goal of leukemia trial",
            "features": {
                "keywords": [
                    "Roche",
                    "combo treatment",
                    "leukemia trial",
                    "positive results"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie, Roche combo treatment meets main goal of leukemia trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "Noteworthy Wednesday Option Activity: DVA, GOGO, ABBV",
            "features": {
                "keywords": [
                    "option activity",
                    "DVA",
                    "GOGO",
                    "ABBV"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Noteworthy Wednesday Option Activity: DVA, GOGO, ABBV",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "SHAREHOLDER ALERT: OPK PVG USAT ABBV CHGG ACHC JT ADNT GOOG CWH OZK DY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines",
            "features": {
                "keywords": [
                    "class action",
                    "deadlines",
                    "investors"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: OPK PVG USAT ABBV CHGG ACHC JT ADNT GOOG CWH OZK DY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia",
            "features": {
                "keywords": [
                    "positive results",
                    "Phase 3 trial",
                    "venetoclax combination",
                    "chronic lymphocytic leukemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie Announces Positive Results from CLL14, a Phase 3 Trial Evaluating a Venetoclax Combination as First-Line Therapy with a Fixed Duration of Treatment in Patients with Chronic Lymphocytic Leukemia",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "AbbVie Falls 3%",
            "features": {
                "keywords": [
                    "falls",
                    "stock price"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Falls 3%",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "class action lawsuit",
                    "investor losses",
                    "schall law firm"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "CLASS ACTION UPDATE for ABBV, JT and OZK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
            "features": {
                "keywords": [
                    "class action update",
                    "abbv",
                    "jt",
                    "ozk"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "CLASS ACTION UPDATE for ABBV, JT and OZK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "FDA approves Novartis' copy of AbbVie bestseller Humira",
            "features": {
                "keywords": [
                    "fda approval",
                    "novartis",
                    "humira",
                    "competition"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "FDA approves Novartis' copy of AbbVie bestseller Humira",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?",
            "features": {
                "keywords": [
                    "q3 earnings",
                    "neurocrine",
                    "nbix"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018",
            "features": {
                "keywords": [
                    "class action",
                    "abbvie",
                    "lead plaintiff deadline"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-10-17",
            "original_text": "What to Expect from AbbVie’s Third-Quarter Earnings",
            "features": {
                "keywords": [
                    "third-quarter earnings",
                    "expectations",
                    "abbvie"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What to Expect from AbbVie’s Third-Quarter Earnings",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]